In a review of the pricey new prostate cancer treatments hitting the market, Reuters directed its spotlight to Medivation's MDV3100, noting its closely watched status as the biotech readies a crucial interim analysis later this year. For Medivation, which has been bitterly disappointed in its studies of the experimental Alzheimer's treatment Dimebon, the cancer data will present a major catalyst on its stock price. "MDV3100 is certainly promising...but we haven't seen the data yet," says Dr. Elizabeth Plimack, an oncologist at Philadelphia's Fox Chase Cancer Center. Report
Source: http://www.fiercebiotech.com/story/medivation-prostate-cancer-drug-back-spotlight/2011-09-20
breaking news usa today hcg diet insight jennifer garner jennifer garner yelp
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.